The Alteration of HDL Protein Composition in Patients With Coronary Heart Disease Before and After Statins Treatment
NCT ID: NCT01543308
Last Updated: 2013-05-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
400 participants
OBSERVATIONAL
2012-02-29
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
So, this study is to conduct in the two following aspects: enlarge the sample size to verify the preliminary results to find new research ideas of pathogenesis and biomarkers for coronary heart disease; and study the changes of HDL protein composition in patients with coronary heart disease before and after statins treatment using proteomics technology in order to find the mechanism of statins pleiotropic effects and indicators for evaluating the treatment effectiveness.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Plaque Inflammation and Dysfunctional HDL in AIM-HIGH
NCT00880178
Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography
NCT06863545
Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI
NCT01293097
the Change of CEM and the Prognosis of Coronary Artery Disease in Real Clinical Practice
NCT03473860
Intensive Statin Treatment for STEMI Patients Undergoing Primary PCI
NCT01033058
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
coronary heart disease
No interventions assigned to this group
healthy control group
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Science and Technology of the People´s Republic of China
OTHER_GOV
Beijing Proteome Research Center
OTHER
Chinese Academy of Medical Sciences, Fuwai Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yan Li-rong
Key Laboratory of Clinical Trial Research in Cardiovascular Drugs
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hong Liu
Role: PRINCIPAL_INVESTIGATOR
Chinese Academy of Medical Sciences, Fuwai Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, FuWai Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-HDL-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.